Compositions and methods for modifying a human dystrophin gene
AssigneeMammoth Biosciences, Inc.
InventorsLucas Benjamin HARRINGTON, Wiputra Jaya HARTONO, Pei-Qi LIU, Darren Bo Yee LO, Renan B. SPER
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions, systems, and methods comprising effector proteins and uses thereof. These effector proteins may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure may leverage the activities of these effector proteins for the modification, detection, and engineering of nucleic acids.
Claims21
A composition that comprises:
- (a) an effector protein comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:
- 1, or a nucleic acid encoding the same, and
- (b) a guide nucleic acid that comprises a spacer sequence that hybridizes to a target sequence of a human dystrophin (DMD) locus, or a nucleic acid encoding the same.
-7. (canceled)
-15. (canceled)
-38. (canceled)
The composition of claim 19, wherein the RT is fused or linked to an aptamer binding protein and wherein the guide nucleic acid comprises an aptamer.
Dependencies are inferred from the claim text.